GLP-1 Insurance Coverage Guide 2026: What's Covered and How to Get It
Medically Reviewed by
Board Certified Internal Medicine
Published
Mar 17, 2026
Last Reviewed
Mar 18, 2026
Sources
5 peer-reviewed
Standard
YMYL / E-E-A-T
GLP-1 Insurance Coverage in 2026: The Landscape
Coverage for GLP-1 weight loss medications in 2026 remains inconsistent and highly plan-dependent. Ozempic and Mounjaro (diabetes-approved drugs) have broader insurance coverage than Wegovy and Zepbound (weight-loss-approved drugs), because many employer plans and Medicare Part D traditionally excluded obesity medications from formularies. This gap is narrowing: the Inflation Reduction Act introduced Medicare weight-loss drug coverage pathways, and the SELECT trial data (2023) showing cardiovascular benefit with semaglutide has pressured commercial plans to expand coverage. But as of early 2026, patients still face a patchwork of coverage rules that require active navigation.
Medicare Part D Coverage for GLP-1 Drugs in 2026
Medicare Part D historically excluded weight-loss drugs, but the Treat and Reduce Obesity Act (TROA), if enacted, would change this. As of early 2026, Medicare covers Ozempic and Mounjaro for enrolled patients with Type 2 diabetes diagnoses, because diabetes coverage was never excluded. Wegovy coverage expanded after the FDA approval for cardiovascular risk reduction (March 2024) — Medicare Part D now covers Wegovy for enrolled beneficiaries with established cardiovascular disease and obesity. Beneficiaries with obesity alone (without a T2D or CVD diagnosis) may still face coverage gaps. Check with your specific Part D plan, as formulary inclusion varies by plan sponsor.
Commercial (Employer) Insurance Coverage
Commercial insurance coverage is the most variable. Large self-funded employer plans set their own formularies — some explicitly cover Wegovy and Zepbound for obesity, while others exclude all weight management medications. Small fully-insured plans are subject to state mandates, which vary: as of 2026, states including Massachusetts, Illinois, and Oregon require obesity drug coverage; most others do not. The key strategy for commercial insurance is to determine whether your plan has an obesity medication benefit, what diagnostic codes trigger coverage (typically E66.x for obesity), and whether your prescribing physician has submitted the correct prior authorization with supporting documentation of BMI, comorbidities, and treatment history.
Manufacturer Savings Programs and Patient Assistance
Both Novo Nordisk and Eli Lilly offer savings cards and patient assistance programs. The Wegovy Savings Offer typically provides Wegovy for as low as $25/month for commercially insured patients who meet eligibility criteria (income and insurance status-based). The Zepbound Savings Card program similarly reduces out-of-pocket costs for eligible commercially insured patients. For uninsured patients with income below 400–600% of the federal poverty level, both manufacturers offer Patient Assistance Programs (PAPs) that may provide the medication at no cost. These programs change frequently — visit NovoCare.com and LillyCaresFoundation.com for current terms.
Medicaid Coverage by State
Medicaid coverage for GLP-1 weight loss drugs varies dramatically by state. States that have expanded Medicaid coverage for obesity pharmacotherapy include Oregon, New York, and several others. Most state Medicaid programs cover Ozempic and Mounjaro for T2D beneficiaries under existing diabetes coverage. Some states cover Wegovy and Zepbound for obesity under specific circumstances with prior authorization. Given the high rates of obesity and diabetes in Medicaid populations, coverage expansion is an active policy area — check your state Medicaid agency website or use the patient navigator at your clinic to verify current formulary status.
What to Do If Your Insurance Denies Coverage
A denial is not the end. First, verify the denial reason — it may be a missing modifier, incorrect diagnosis code, or incomplete PA documentation. Ask your physician to resubmit with a detailed letter of medical necessity. Second, file a formal appeal within the plan's deadline (typically 30–60 days from denial). Include peer-reviewed evidence of efficacy, your cardiovascular risk factors, comorbidities, and prior treatment history. Third, if internal appeal fails, request an external review — this is a federal right under the ACA for fully-insured plans. Fourth, simultaneously apply for the manufacturer's savings program or patient assistance program while appealing, so you don't lose access to medication during the process.
GLP-1 Drug Price Comparison
Updated March 2026 · Prices shown are average monthly retail costs. Actual costs vary by pharmacy and insurance plan.
| Drug | Indication | Admin | Without Insurance | With Insurance | Avg. Weight Loss | |
|---|---|---|---|---|---|---|
WegovyMost Popular Novo Nordisk | Weight Loss | Weekly Injection | $1,349/mo | $25–$200/mo | ~15–20% | Check Price |
Ozempic Novo Nordisk | Type 2 Diabetes | Weekly Injection | $935/mo | $25–$150/mo | ~12–15% | Check Price |
ZepboundBest Results Eli Lilly | Weight Loss | Weekly Injection | $1,059/mo | $25–$175/mo | ~20–22% | Check Price |
Mounjaro Eli Lilly | Type 2 Diabetes | Weekly Injection | $1,069/mo | $25–$150/mo | ~18–20% | Check Price |
RybelsusNeedle-Free Novo Nordisk | Type 2 Diabetes | Daily Pill | $850/mo | $10–$100/mo | ~5–8% | Check Price |
Without insurance
$1,349/mo
With insurance
$25–$200/mo
Avg. weight loss
~15–20%
Administration
Weekly Injection
Without insurance
$935/mo
With insurance
$25–$150/mo
Avg. weight loss
~12–15%
Administration
Weekly Injection
Without insurance
$1,059/mo
With insurance
$25–$175/mo
Avg. weight loss
~20–22%
Administration
Weekly Injection
Without insurance
$1,069/mo
With insurance
$25–$150/mo
Avg. weight loss
~18–20%
Administration
Weekly Injection
Without insurance
$850/mo
With insurance
$10–$100/mo
Avg. weight loss
~5–8%
Administration
Daily Pill
* Prices are estimates based on average pharmacy retail pricing. Always verify with your pharmacy or insurance. Some links are affiliate links — we may earn a commission at no extra cost to you.
Frequently Asked Questions
These answers are for informational purposes only. Always consult your physician for personalized medical advice.
Was this article helpful?
Scientific References & Further Reading
- Wilding JPH et al. — Once-Weekly Semaglutide in Adults with Overweight or Obesity. NEJM 2021.
- Jastreboff AM et al. — Tirzepatide Once Weekly for the Treatment of Obesity. NEJM 2022.
- FDA Drug Approvals Database — GLP-1 Receptor Agonists. U.S. Food & Drug Administration.
- PubMed — GLP-1 Receptor Agonist Research Index. National Library of Medicine.
- Mayo Clinic — GLP-1 Agonists for Type 2 Diabetes and Obesity. Mayo Clinic Proceedings.
This content is produced in accordance with GLP-1 Health's editorial standards and is based on peer-reviewed clinical evidence from the sources cited above. It does not constitute medical advice. Always consult a licensed healthcare provider before starting any medication.
